Roberto Pili

  • 10704 Citations
  • 51 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1990 2019

Article
17 Citations (Scopus)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journalArticle

Microvessels
Heterografts
Colonic Neoplasms
Neoplasms
sunitinib
5 Citations (Scopus)

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journalArticle

30 Citations (Scopus)

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Smoking
Survival
Hypertension
6 Citations (Scopus)

Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice

Pili, R., Chang, J., Muhlhauser, J., Crystal, R. G., Capogrossi, M. C. & Passaniti, A., 1997, In : International Journal of Cancer. 73, 2, p. 258-263 6 p.

Research output: Contribution to journalArticle

Fibroblast Growth Factor 1
Adenoviridae
Nude Mice
Genes
Growth
60 Citations (Scopus)

Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo

Cirielli, C., Riccioni, T., Yang, C., Pili, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A. & Capogrossi, M. C., 1995, In : International Journal of Cancer. 63, 5, p. 673-679 7 p.

Research output: Contribution to journalArticle

Melanoma
Apoptosis
Genes
Neoplasms
DNA Fragmentation
257 Citations (Scopus)

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., Wilding, G., Cella, D., Wagner, L., Matin, S., Kuzel, T. M., Sexton, W. J., Wong, Y. N., Choueiri, T. K., Pili, R., Puzanov, I. & 5 others, Kohli, M., Stadler, W., Carducci, M., Coomes, R. & Dipaola, R. S., May 14 2016, In : The Lancet. 387, 10032, p. 2008-2016 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Placebos
sorafenib
sunitinib
Disease-Free Survival
1 Citation (Scopus)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Pili, R., Van Der Vliet, H. J., De Gruijl, T. D. & Verheul, H. M. W., Oct 11 2016, In : British Journal of Cancer. 115, 8, p. 940-948 9 p.

Research output: Contribution to journalArticle

Biological Assay
Vascular Endothelial Growth Factor A
Anti-Idiotypic Antibodies
Neoplasms
Therapeutics
47 Citations (Scopus)

A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells

Ziegelstein, R. C., Spurgeon, H. A., Pili, R., Passaniti, A., Cheng, L., Corda, S., Lakatta, E. G. & Capogrossi, M. C., 1994, In : Circulation Research. 74, 1, p. 151-156 6 p.

Research output: Contribution to journalArticle

Ryanodine
Endothelial Cells
Bradykinin
Aorta
Buffers
11 Citations (Scopus)

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma

Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Pili, R. & Baker, S. D., Jan 17 2007, In : Journal of Pharmaceutical and Biomedical Analysis. 43, 2, p. 784-787 4 p.

Research output: Contribution to journalArticle

Plasma (human)
formic acid
Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
10 Citations (Scopus)

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journalArticle

DNA Methylation
Renal Cell Carcinoma
Formaldehyde
Chromatin
Neoplasms
107 Citations (Scopus)

Altered angiogenesis underlying age-dependent changes in tumor growth

Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R. & Passaniti, A., Sep 7 1994, In : Journal of the National Cancer Institute. 86, 17, p. 1303-1314 12 p.

Research output: Contribution to journalArticle

Angiogenesis
Tumor Growth
Tumors
Tumor
Dependent
46 Citations (Scopus)

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F., Pili, R., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., Mamlouk, K., Ferrante, K. J. & Taplin, M. E., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1356-1363 8 p.

Research output: Contribution to journalArticle

Castration
Androgen Receptors
Prostatic Neoplasms
Safety
Therapeutics
56 Citations (Scopus)

A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A. & Wagner, H. N., Jan 2005, In : Bioconjugate Chemistry. 16, 1, p. 43-50 8 p.

Research output: Contribution to journalArticle

Technetium
Bombesin
Peptides
Bombesin Receptors
Liver
19 Citations (Scopus)

A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Pili, R., Pomper, M., Carducci, M. & Wagner, H. N., Nov 2004, In : Bioconjugate Chemistry. 15, 6, p. 1416-1423 8 p.

Research output: Contribution to journalArticle

Technetium
Bombesin
Pharmacokinetics
Peptides
Bombesin Receptors
79 Citations (Scopus)

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H. & Carducci, M. A., Sep 2011, In : European Journal of Cancer. 47, 13, p. 1955-1961 7 p.

Research output: Contribution to journalArticle

Angiotensins
Renal Cell Carcinoma
Logistic Models
Survival
Angiotensin Receptor Antagonists
4 Citations (Scopus)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Protein-Tyrosine Kinases
Neoplasms
Neutropenia
Vascular Endothelial Growth Factor A

Antitumor activity and mechanistic characterization of APE1/ReF-1 inhibitors in bladder cancer

Fishel, M. L., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G. E., Zhang, C., Pili, R., Kelley, M. R. & Jerde, T. J., Jan 1 2019, In : Molecular cancer therapeutics. 18, 11, p. 1947-1960 14 p.

Research output: Contribution to journalArticle

Endonucleases
Urinary Bladder Neoplasms
Oxidation-Reduction
Cisplatin
Cell Proliferation
48 Citations (Scopus)

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L. & Pili, R., Aug 1 2007, In : Prostate. 67, 11, p. 1182-1193 12 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Prostatic Neoplasms
Acetylation
Growth
Histones
43 Citations (Scopus)

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Kato, Y., Salumbides, B. C., Wang, X. F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P. & Pili, R., Jan 2007, In : Molecular Cancer Therapeutics. 6, 1, p. 70-81 12 p.

Research output: Contribution to journalArticle

NSC 153174
Isotretinoin
Histone Deacetylase Inhibitors
Melanoma
Tretinoin
26 Citations (Scopus)

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.

Research output: Contribution to journalArticle

Castration
Prostate
Prostatic Neoplasms
Stem Cells
Antigens

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Maximum Tolerated Dose
Neoplasms
Safety
Vascular Endothelial Growth Factor A
45 Citations (Scopus)

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Safety
Neoplasms
Carcinoma
53 Citations (Scopus)

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K., Hammers, H., Sweeney, C., Kim, K., Perlman, S., Arnott, J., Sidor, C., Wilding, G. & Liu, G., Dec 2011, In : Investigational New Drugs. 29, 6, p. 1465-1474 10 p.

Research output: Contribution to journalArticle

Nanoparticles
Prostatic Neoplasms
Medical Futility
Gastrointestinal Hemorrhage
Hyponatremia
46 Citations (Scopus)

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Nanoparticles
Disease Progression
2-methoxyestradiol
sunitinib
132 Citations (Scopus)

A Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C. & Liu, G., Dec 1 2008, In : Clinical Cancer Research. 14, 23, p. 7940-7946 7 p.

Research output: Contribution to journalArticle

tanespimycin
Prostatic Neoplasms
Prostate-Specific Antigen
Hormones
Fatigue
10 Citations (Scopus)

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Sunkara, U., Walczak, J. R., Summerson, L., Rogers, T., Eisenberger, M., Denmeade, S., Pili, R., Huff, C. A., Sinibaldi, V. & Carducci, M. A., Jan 2004, In : Journal of Interferon and Cytokine Research. 24, 1, p. 37-41 5 p.

Research output: Contribution to journalArticle

temozolomide
Renal Cell Carcinoma
Interferons
Chills
Melanoma
1 Citation (Scopus)

A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

Resta, L. P., Pili, R., Eisenberger, M. A., Spitz, A., King, S., Porter, J., Franke, A., Boinpally, R., Carducci, M. A. & Sweeney, C. J., Feb 2011, In : Cancer Chemotherapy and Pharmacology. 67, 2, p. 431-438 8 p.

Research output: Contribution to journalArticle

Mitoxantrone
Tumors
Neoplasms
Toxicity
Prednisone

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Pili, R., Jegede, O., Carducci, M. A., Manola, J., Groteluschen, D. L., Appleman, L. L., Liu, G., Shanks, J. C., Dakhil, S. R., Dutcher, J. & DiPaola, R. S., Jan 5 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease Progression
Vascular Endothelial Growth Factor Receptor
aflibercept
Proteinuria
7 Citations (Scopus)

Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients

Bartoloni, C., Guidi, L., Pili, R., Lewis, Z. A., Tricerri, A., Cursi, F., Gentiloni, N., Cortesi, E. & Gambassi, G., 1993, In : Oncology. 50, 1, p. 27-34 8 p.

Research output: Contribution to journalArticle

Gastrointestinal Neoplasms
Antigen-Antibody Complex
Inflammatory Bowel Diseases
Immune Sera
Melanoma
32 Citations (Scopus)

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work

Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Randomized Controlled Trials
Placebos
Bone and Bones
42 Citations (Scopus)

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journalArticle

Diphosphonates
Renal Cell Carcinoma
Disease-Free Survival
Neoplasm Metastasis
Bone and Bones
110 Citations (Scopus)

CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models

Ruggeri, B., Singh, J., Gingrich, D., Angeles, T., Albom, M., Chang, H., Robinson, C., Hunter, K., Dobrzanski, P., Jones-Bolin, S., Aimone, L., Klein-Szanto, A., Herbert, J. M., Bono, F., Schaeffer, P., Casellas, P., Bourie, B., Pili, R., Isaacs, J., Ator, M. & 4 others, Hudkins, R., Vaught, J., Mallamo, J. & Dionne, C., Sep 15 2003, In : Cancer Research. 63, 18, p. 5978-5991 14 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Phosphotransferases
Nude Mice
19 Citations (Scopus)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Shen, L. & Pili, R., 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
Histone Deacetylases
Regulatory T-Lymphocytes
Immunotherapy
Immune Tolerance
82 Citations (Scopus)

Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PLoS One. 7, 1, e30815.

Research output: Contribution to journalArticle

kidney neoplasms
histone deacetylase
Histone Deacetylase Inhibitors
T-cells
Kidney Neoplasms
237 Citations (Scopus)

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α

Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. & Pili, R., Sep 1 2006, In : Cancer Research. 66, 17, p. 8814-8821 8 p.

Research output: Contribution to journalArticle

Hypoxia-Inducible Factor 1
Histone Deacetylases
Histone Deacetylase Inhibitors
Transcriptional Activation
Proteins
29 Citations (Scopus)

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L., Cheng, L., Nassiri, M., Davidson, D., Rushing, D. A., Loehrer, P., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T., Helft, P., Shahda, S. & 2 others, O'Neil, B. H. & Schneider, B., 2016, In : Oncotarget. 7, 35, p. 56491-56500 10 p.

Research output: Contribution to journalArticle

Precision Medicine
Disease-Free Survival
Neoplasms
Therapeutics
Standard of Care
15 Citations (Scopus)

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation

Wang, J., Papanicolau-Sengos, A., Chintala, S., Wei, L., Liu, B., Hu, Q., Miles, K. M., Conroy, J. M., Glenn, S. T., Costantini, M., Magi-Galluzzi, C., Signoretti, S., Choueiri, T., Gallucci, M., Sentinelli, S., Fazio, V. M., Poeta, M. L., Liu, S., Morrison, C. & Pili, R., May 24 2016, In : Oncotarget. 7, 21, p. 29901-29915 15 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Up-Regulation
Genes
Cisplatin
Single Nucleotide Polymorphism
11 Citations (Scopus)

Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.

Research output: Contribution to journalArticle

Histone Deacetylase Inhibitors
T-cells
Interleukin-2
Tumors
Melanoma
114 Citations (Scopus)

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis

Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A., Feb 15 2001, In : Cancer Research. 61, 4, p. 1477-1485 9 p.

Research output: Contribution to journalArticle

Phenylbutyrates
Isotretinoin
Prostate
Growth
Neoplasms
25 Citations (Scopus)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

Pili, R., Liu, G., Chintala, S., Verheul, H., Rehman, S., Attwood, K., Lodge, M. A., Wahl, R., Martin, J. I., Miles, K. M., Paesante, S., Adelaiye, R., Godoy, A., King, S., Zwiebel, J. & Carducci, M. A., Feb 21 2017, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Clinical Trials, Phase I
Histone Deacetylase Inhibitors
Renal Cell Carcinoma
Disease-Free Survival
94 Citations (Scopus)

Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors

Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P. & Pili, R., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3589-3597 9 p.

Research output: Contribution to journalArticle

Hypoxia-Inducible Factor 1
Histone Deacetylase Inhibitors
Sirolimus
Human Umbilical Vein Endothelial Cells
Western Blotting
51 Citations (Scopus)

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular Cancer Therapeutics. 14, 1, p. 101-110 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Growth
44 Citations (Scopus)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.

Research output: Contribution to journalArticle

Histone Deacetylases
Androgen Receptors
Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
DNA Damage
30 Citations (Scopus)

Concordance of cancer patients' function, symptoms, and supportive care needs

Snyder, C. F., Garrett-Mayer, E., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Oct 2009, In : Quality of Life Research. 18, 8, p. 991-998 8 p.

Research output: Contribution to journalArticle

Neoplasms
Observational Studies
Cross-Sectional Studies
14 Citations (Scopus)

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in MicroRNA expression

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R., Miles, K. M., Wang, D., Liu, S., Atadja, P., Carducci, M. A. & Pili, R., Nov 7 2011, In : PLoS One. 6, 11, e27178.

Research output: Contribution to journalArticle

Histone Deacetylases
Androgen Receptors
MicroRNAs
microRNA
histones
39 Citations (Scopus)

Contrasting effects of sunitinib within in vivo models of metastasis

Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., Weverwijk, A. V., Robertson, D., Soffe, J., Erler, J. T., Pili, R., Springer, C. J., Mather, S. J. & Reynolds, A. R., 2012, In : Angiogenesis. 15, 4, p. 623-641 19 p.

Research output: Contribution to journalArticle

Tumors
Neoplasm Metastasis
Neoplasms
Lung
Cells
17 Citations (Scopus)

Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer

Ciamporcero, E., Daga, M., Pizzimenti, S., Roetto, A., Dianzani, C., Compagnone, A., Palmieri, A., Ullio, C., Cangemi, L., Pili, R. & Barrera, G., Feb 1 2018, In : Free Radical Biology and Medicine. 115, p. 447-457 11 p.

Research output: Contribution to journalArticle

Crosstalk
Urinary Bladder Neoplasms
Antioxidants
Cells
Transcription Factors
3 Citations (Scopus)

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., Rak, M., Attwood, K., Johnson, C., Morrison, C., Pili, R., Chatta, G., Guru, K., Gueron, G., McNally, L., Wang, J. & Woloszynska-Read, A., Dec 1 2017, In : Cell Death and Disease. 8, 12, 3217.

Research output: Contribution to journalArticle

decitabine
Urinary Bladder Neoplasms
Interleukin-6
Muscles
DNA
9 Citations (Scopus)

Development of a castrate resistant transplant tumor model of prostate cancer

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R. & Pili, R., May 1 2012, In : Prostate. 72, 6, p. 587-591 5 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Transplants
Neoplasms
Androgens
Androgen Receptors
2 Citations (Scopus)

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model

Affronti, H. C., Long, M. D., Rosario, S. R., Gillard, B. M., Karasik, E., Boerlin, C. S., Pellerite, A. J., Foster, B. A., Attwood, K., Pili, R., Wilton, J. H., Campbell, M. J. & Smiraglia, D. J., Jan 1 2017, In : Oncotarget. 8, 61, p. 103758-103774 17 p.

Research output: Contribution to journalArticle

Folic Acid
Prostatic Neoplasms
Recurrence
Androgens
Heterografts